Ligand Pharmaceuticals Statistics
Total Valuation
Aramark has a market cap or net worth of $10.42 billion. The enterprise value is $16.47 billion.
| Market Cap | 10.42B |
| Enterprise Value | 16.47B |
Important Dates
The last earnings date was Tuesday, August 5, 2025, before market open.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | Aug 6, 2025 |
Share Statistics
Aramark has 262.85 million shares outstanding. The number of shares has increased by 0.99% in one year.
| Current Share Class | 262.85M |
| Shares Outstanding | 262.85M |
| Shares Change (YoY) | +0.99% |
| Shares Change (QoQ) | -0.78% |
| Owned by Insiders (%) | 0.44% |
| Owned by Institutions (%) | 93.56% |
| Float | 245.21M |
Valuation Ratios
The trailing PE ratio is 28.80 and the forward PE ratio is 17.75. Aramark's PEG ratio is 1.04.
| PE Ratio | 28.80 |
| Forward PE | 17.75 |
| PS Ratio | 0.58 |
| Forward PS | 0.52 |
| PB Ratio | 3.33 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 37.02 |
| P/OCF Ratio | 13.55 |
| PEG Ratio | 1.04 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.28, with an EV/FCF ratio of 58.65.
| EV / Earnings | 45.53 |
| EV / Sales | 0.92 |
| EV / EBITDA | 13.28 |
| EV / EBIT | 21.25 |
| EV / FCF | 58.65 |
Financial Position
The company has a current ratio of 1.29, with a Debt / Equity ratio of 2.14.
| Current Ratio | 1.29 |
| Quick Ratio | 1.06 |
| Debt / Equity | 2.14 |
| Debt / EBITDA | 2.55 |
| Debt / FCF | 23.57 |
| Interest Coverage | 2.16 |
Financial Efficiency
Return on equity (ROE) is 11.96% and return on invested capital (ROIC) is 5.11%.
| Return on Equity (ROE) | 11.96% |
| Return on Assets (ROA) | 3.75% |
| Return on Invested Capital (ROIC) | 5.11% |
| Return on Capital Employed (ROCE) | 7.35% |
| Revenue Per Employee | $67,027 |
| Profits Per Employee | $1,356 |
| Employee Count | 266,680 |
| Asset Turnover | 1.38 |
| Inventory Turnover | 39.48 |
Taxes
In the past 12 months, Aramark has paid $119.80 million in taxes.
| Income Tax | 119.80M |
| Effective Tax Rate | 24.87% |
Stock Price Statistics
The stock price has increased by +14.81% in the last 52 weeks. The beta is 1.40, so Aramark's price volatility has been higher than the market average.
| Beta (5Y) | 1.40 |
| 52-Week Price Change | +14.81% |
| 50-Day Moving Average | 41.63 |
| 200-Day Moving Average | 38.29 |
| Relative Strength Index (RSI) | 36.69 |
| Average Volume (20 Days) | 2,034,926 |
Short Selling Information
The latest short interest is 8.12 million, so 3.09% of the outstanding shares have been sold short.
| Short Interest | 8.12M |
| Short Previous Month | 8.86M |
| Short % of Shares Out | 3.09% |
| Short % of Float | 3.31% |
| Short Ratio (days to cover) | 4.65 |
Income Statement
In the last 12 months, Aramark had revenue of $17.87 billion and earned $361.67 million in profits. Earnings per share was $1.36.
| Revenue | 17.87B |
| Gross Profit | 2.78B |
| Operating Income | 774.95M |
| Pretax Income | 424.03M |
| Net Income | 361.67M |
| EBITDA | 1.24B |
| EBIT | 774.95M |
| Earnings Per Share (EPS) | $1.36 |
Balance Sheet
The company has $545.19 million in cash and $6.62 billion in debt, giving a net cash position of -$6.07 billion or -$23.10 per share.
| Cash & Cash Equivalents | 545.19M |
| Total Debt | 6.62B |
| Net Cash | -6.07B |
| Net Cash Per Share | -$23.10 |
| Equity (Book Value) | 3.10B |
| Book Value Per Share | 11.74 |
| Working Capital | 790.54M |
Cash Flow
In the last 12 months, operating cash flow was $767.09 million and capital expenditures -$486.32 million, giving a free cash flow of $280.76 million.
| Operating Cash Flow | 767.09M |
| Capital Expenditures | -486.32M |
| Free Cash Flow | 280.76M |
| FCF Per Share | $1.07 |
Margins
Gross margin is 15.56%, with operating and profit margins of 4.34% and 2.02%.
| Gross Margin | 15.56% |
| Operating Margin | 4.34% |
| Pretax Margin | 2.69% |
| Profit Margin | 2.02% |
| EBITDA Margin | 6.94% |
| EBIT Margin | 4.34% |
| FCF Margin | 1.57% |
Dividends & Yields
This stock pays an annual dividend of $0.42, which amounts to a dividend yield of 1.07%.
| Dividend Per Share | $0.42 |
| Dividend Yield | 1.07% |
| Dividend Growth (YoY) | 10.53% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 30.93% |
| Buyback Yield | -0.99% |
| Shareholder Yield | 0.08% |
| Earnings Yield | 3.48% |
| FCF Yield | 2.70% |
Analyst Forecast
The average price target for Aramark is $45.44, which is 14.63% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $45.44 |
| Price Target Difference | 14.63% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 6.92% |
| EPS Growth Forecast (5Y) | 26.79% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Aramark has an Altman Z-Score of 2.23 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.23 |
| Piotroski F-Score | 7 |